Immunic adds Elena Ridloff to board ahead of Phase 3 MS readout
The company also detailed the separation terms for former CEO Daniel Vitt as he transitions to a consulting and advisory role.
SEC filing
Latest
3 stories
Wednesday, September 16
Tuesday, August 11
Wednesday, August 5
Kymera moves up KT-621 atopic dermatitis data after fast enrollment
Faster-than-planned enrollment in the STAT6 degrader's Phase 2b trial pulls the readout forward to year-end 2026 and sets up an earlier Phase 3 start.
SEC filing